Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BLCO
Upturn stock ratingUpturn stock rating

Bausch + Lomb Corp (BLCO)

Upturn stock ratingUpturn stock rating
$13.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BLCO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

15 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $14.29

Year Target Price $14.29

Analyst’s Price TargetsFor last 52 week
$14.29Target price
Low$10.45
Current$13.01
high$21.69

Analysis of Past Performance

Type Stock
Historic Profit -31.89%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.38B USD
Price to earnings Ratio -
1Y Target Price 14.29
Price to earnings Ratio -
1Y Target Price 14.29
Volume (30-day avg) 15
Beta 0.56
52 Weeks Range 10.45 - 21.69
Updated Date 06/29/2025
52 Weeks Range 10.45 - 21.69
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.02

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -7.5%
Operating Margin (TTM) -5.37%

Management Effectiveness

Return on Assets (TTM) 0.61%
Return on Equity (TTM) -5.36%

Valuation

Trailing PE -
Forward PE 22.68
Enterprise Value 9004054544
Price to Sales(TTM) 0.91
Enterprise Value 9004054544
Price to Sales(TTM) 0.91
Enterprise Value to Revenue 1.86
Enterprise Value to EBITDA 17.94
Shares Outstanding 353396992
Shares Floating 41994124
Shares Outstanding 353396992
Shares Floating 41994124
Percent Insiders 88.17
Percent Institutions 11.01

Analyst Ratings

Rating 4
Target Price 14.29
Buy 3
Strong Buy 3
Buy 3
Strong Buy 3
Hold 8
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bausch + Lomb Corp

stock logo

Company Overview

overview logo History and Background

Bausch + Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods store, it grew to become a global leader in eye health products, including contact lenses, lens care products, pharmaceuticals, and surgical devices. It has been involved in many eye health milestones and has undergone multiple changes in ownership.

business area logo Core Business Areas

  • Vision Care: Develops, manufactures, and markets a broad range of contact lenses and lens care products, including daily disposable, reusable, and specialty contact lenses.
  • Ophthalmic Pharmaceuticals: Offers a wide array of prescription and over-the-counter ophthalmic pharmaceuticals, including treatments for glaucoma, dry eye, and other eye conditions.
  • Surgical: Provides surgical devices, instruments, and technologies for cataract and refractive surgery.

leadership logo Leadership and Structure

Brent Saunders serves as the Chairman and CEO. The company has a typical corporate structure with various departments reporting to the executive team.

Top Products and Market Share

overview logo Key Offerings

  • ULTRA Contact Lenses: Monthly disposable contact lenses known for comfort and moisture retention. Competitors include Alcon's Air Optix and CooperVision's Biofinity. Market share data is proprietary, but ULTRA is considered a leading brand in the monthly lens category. Revenue from this product is proprietary. Competitors: Alcon, Johnson & Johnson, CooperVision
  • Biotrue ONEday Contact Lenses: Daily disposable contact lenses that mimic the natural moisture of the eye. Competitors include Alcon's Dailies Total1 and Johnson & Johnson's 1-Day Acuvue Moist. Market share data is proprietary, but Biotrue ONEday is a significant player in the daily lens market. Revenue from this product is proprietary. Competitors: Alcon, Johnson & Johnson, CooperVision
  • Lumify: Over-the-counter eye drops that reduce redness. Competitors include Visine and Clear Eyes. Market share data indicates Lumify holds a significant portion of the redness reliever market. Revenue from this product is proprietary. Competitors: Visine, Clear Eyes

Market Dynamics

industry overview logo Industry Overview

The eye health market is driven by an aging population, increasing prevalence of eye conditions (e.g., myopia, dry eye), and technological advancements in vision correction. It is a growing market with strong demand for contact lenses, ophthalmic pharmaceuticals, and surgical solutions.

Positioning

Bausch + Lomb is a major player in the eye health industry, with a broad product portfolio and a strong brand reputation. It competes with other large companies but maintains a competitive advantage through innovation and established market presence.

Total Addressable Market (TAM)

The global eye care market is estimated to be worth hundreds of billions of dollars. Bausch + Lomb is positioned to capture a significant portion of this TAM through its diverse product offerings and global reach.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition
  • Broad product portfolio
  • Global distribution network
  • Established market presence
  • Strong R&D capabilities

Weaknesses

  • High debt levels
  • Exposure to generic competition in pharmaceuticals
  • Dependence on key products
  • Slower growth in certain segments

Opportunities

  • Expanding into emerging markets
  • Developing innovative products and technologies
  • Acquiring complementary businesses
  • Capitalizing on the growing demand for eye health products

Threats

  • Intense competition
  • Regulatory changes
  • Economic downturns
  • Technological disruptions
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • ALC
  • JNJ
  • COO

Competitive Landscape

Bausch + Lomb competes with other major players in the eye health industry. Each competitor has strengths in different products or areas that contribute to the competitive landscape.

Major Acquisitions

DiaMedica Therapeutics Inc.

  • Year: 2024
  • Acquisition Price (USD millions): 775
  • Strategic Rationale: Enhance pharmaceutical offerings in the retina segment.

Growth Trajectory and Initiatives

Historical Growth: Bausch + Lomb's historical growth has been influenced by factors such as acquisitions, product launches, and market conditions.

Future Projections: Future growth projections are based on analyst estimates. Refer to financial data for current information

Recent Initiatives: Recent strategic initiatives include focusing on core product areas, investing in R&D, and expanding into emerging markets.

Summary

Bausch + Lomb is a significant player in the eye health market with a rich history and a diverse product portfolio. Its strong brand recognition and global reach are key strengths. However, it faces challenges such as high debt and intense competition. The company can capitalize on growth opportunities through innovation and expansion into emerging markets, but it must also navigate regulatory hurdles and technological disruptions.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications
  • Market research reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change, so you should always consult with a financial professional before making any investment decisions. Market share data is based on estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bausch + Lomb Corp

Exchange NYSE
Headquaters Vaughan, ON, Canada
IPO Launch date 2022-05-06
CEO & Chairman Mr. Brenton L. Saunders J.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 13500
Full time employees 13500

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.